Skip to main content

Table 2 Treatment outcomes and failures at 6-monthly intervals

From: A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis

 

Baseline

6 months

12 months

18 months

24 months

QMGS

     

AZA, median (IQR)

20.0 (11; 24)

7.0 (5; 8)

7.0 (5; 13)

5.0 (3; 10)

6.0 (3; 8)

MTX, median (IQR)

19.5 (16; 24)

7.5 (4; 11)

7.5 (6; 9)

8.0 (6; 10)

8.0 (6; 9)

MG-ADL

     

AZA, median (IQR)

6.0 (3; 8)

3.0 (0; 5)

2.0 (0; 6)

1.0 (0; 1)

0 (0; 1)

MTX, median (IQR)

7.5 (4; 10)

1.0 (0; 5)

1.0 (0; 3)

0.5 (0; 1)

0 (0; 1)

MMS*

     

AZA, n (%)

 

2/15 (13)

4/15 (27)

5/15 (33)

7/15 (53)

MTX, n (%)

 

3/16 (19)

5/16 (31)

5/16 (33)

9/16 (56)

Period in months

 

0-6

6-12

12-18

18-24

Treatment failures, n

     

A/E withdrawals: AZA

 

2/15

2/13**

-

-

A/E withdrawals: MTX

 

2/16

-

-

-

MG relapses: AZA

 

4/15#

2/13##

-

-

MG relapses: MTX

 

3/16#

0/14

-

-

  1. p > 0.05 for all comparisons. QMGS refers to quantitative MG score.
  2. * MMS or minimal manifestation status refers to a) cumulative proportions in an intention to treat analysis and b) only to subjects with MMS maintained until the end of the study.
  3. A/E refers to adverse events. ** includes 1 serious A/E: died of myocardial infarction.
  4. # 2 subjects in each group received either a course of plasma exchange (P/E) or IVIg.
  5. ## one subject received P/E.
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us